Abcam signs licence deal with Roche
Abcam plc in Cambridge, which supplies life science research tools, has entered into a definitive licence agreement with Roche. Financial terms have not been disclosed.
Abcam will obtain the exclusive rights to the product portfolio of California company Spring Bioscience Corporation in the research use only (RUO) field of use, comprising a total of approximately 760 unique products.
Roche, which acquired Spring in 2007, will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.
The core portfolio consists of 243 recombinant rabbit monoclonal antibodies, branded Spring Proprietary Clones (SP Clones), which have been optimised for immunohistochemistry (IHC). The agreement also covers approximately 500 additional products, predominantly other monoclonal and polyclonal antibodies.
All products will be sold under the Abcam brand, inclusive of SP branding, and are expected to be available through Abcam.com from February 21.
Abcam has further been granted exclusive RUO rights for all future products developed by Spring that Roche requests to be commercialised in the RUO field of use for an initial period of 10 years and then extendable on mutually agreeable terms.
Abcam CEO Alan Hirzel said: “This agreement represents an exciting step in the ongoing collaborative and long-term relationship between Abcam and Roche.
“By incorporating the Spring Bioscience antibodies into our portfolio we will be able to better assist our customers, providing them with more products for their most important targets, faster.
“Abcam is excited to partner with Spring Bioscience, commonly recognised as a leading manufacturer of IHC antibodies, furthering Abcam’s mission to provide customers with the highest quality recombinant antibodies for their research.”
• PHOTOGRAPH SHOWS: Alan Hirzel